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Dendritic cells (DCs) are critically involved in the determination of immunity vs. tolerance. 
Hence, DCs are key regulators of immune responses either favoring or disfavoring 
fetal survival. Several factors were proposed to modulate DC phenotype and function 
during pregnancy. Here, we studied whether the pregnancy hormone human chorionic 
gonadotropin (hCG) is involved in DC regulation. In vitro, bone marrow-derived DCs 
(BMDCs) were stimulated in the presence or absence of urine-purified or recombinant 
hCG (rhCG) preparations. Subsequently, BMDC maturation was assessed. Cytokine 
secretion of activated BMDCs and their capability to enforce TH1, TH2, TH17, or Treg 
cell differentiation was determined after rhCG treatment. Moreover, the in vivo potential 
of hCG-modulated BMDCs to influence pregnancy outcome, Treg cell number, and local 
cytokine expression was evaluated after adoptive transfer in a murine abortion-prone 
model before and after conception. Both hCG preparations impaired the maturation 
process of BMDCs. rhCG treatment did neither alter cytokine secretion by BMDCs nor 
their ability to drive TH1, TH2, or TH17 differentiation. rhCG-treated BMDCs augmented 
the number of Treg cells within the T cell population. Adoptive transfer of rhCG-treated 
BMDCs after conception did not influence pregnancy outcome. However, transfer of 
hCG-treated BMDCs prior to mating had a protective effect on pregnancy. This positive 
effect was accompanied by increased Treg cell numbers and decidual IL-10 and TGF-β 
expression. Our results unveil the importance of hCG in retaining DCs in a tolerogenic 
state, thereby promoting Treg cell increment and supporting fetal survival.
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inTrODUcTiOn
Dendritic cells (DCs) are situated at the interface between the innate and the adaptive immune 
system and are, therefore, critically involved in the initiation or suppression of adaptive immune 
responses. During pregnancy, the immune system faces a dilemma. On the one hand, it has to grant 
immunity against potential harmful pathogens while, at the same time, it has to tolerate the foreign 
antigens expressed by the semi-allogeneic fetus. As DCs are key regulators in the balance between 
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tolerance and immunity, they are proposed to be pivotal players 
in the decision whether the fetus is tolerated or rejected.
Human DCs represent approximately 1.7% of all CD45+ cells 
in the decidua and the vast majority displays a myeloid phenotype 
(1). In normal pregnancy, Kämmerer and colleagues described 
a unique DC population in the human decidua displaying an 
immature phenotype with a high proliferative potential and low 
T cell stimulatory capacity (2). Another study identified a subset 
of tolerogenic DCs in human decidual tissue, which produce high 
amounts of IL-10 (3). In mice, an accumulation of DCs has been 
reported in the receptive phase of the estrus cycle in uterine tissue 
even before pregnancy arises. DC clusters were located close to 
the uterine lumen or small blood vessels on the anti-mesometrial 
side (4). During normal murine pregnancy, the highest number 
of total DCs could be detected at early pregnancy stages where 
the average density of CD11c+ cells was 1.3% of all nucleated cells 
in the decidua. Within the total DC pool, the relative percent-
age of lymphoid DCs was highest at mid gestation, while the 
relative percentage of myeloid DCs was highest at early and late 
gestation (5). One study by Plaks and colleagues confirmed the 
indispensable role of murine uterine DCs for the implantation 
process (6), while two other human studies proposed an associa-
tion between an elevated number of mature DCs and recurrent 
spontaneous abortions (7, 8). Thus, it is tempting to speculate 
that dysregulations in the number of different DC subpopulations 
and their maturation states may positively or negatively influ-
ence pregnancy outcome. However, the factors and underlying 
mechanisms affecting the phenotype and function of DCs during 
pregnancy are still not completely understood.
Several human and murine studies proposed trophoblast-
associated factors as potential candidates in DC modulation 
(9, 10). This includes factors, such as soluble thymic stromal 
lymphopoitin and pregnancy-specific glycoprotein (11, 12). 
After being in contact with trophoblasts, DCs have been shown to 
retain an immature phenotype, produce IL-10 and TGF-β rather 
than IL-12 and TNF-α, have a reduced capability to stimulate 
allogeneic immune responses, and enforce TH2 differentiation 
and Treg cell induction (9, 11, 12). These mechanisms are all 
involved in fetal tolerance.
Besides these, female sex hormones such as progesterone and 
estrogen were implied to impact DCs. Hormonal stimulation of 
activated bone marrow-derived DCs (BMDCs) resulted in the 
majority of studies in an impaired upregulation of MHCII mol-
ecules and costimulatory molecules associated with a decreased 
potential to secrete pro-inflammatory cytokines. In line with 
a hormonal-driven induction of a tolerogenic phenotype in 
activated BMDCs, their T cell stimulatory capacity was reduced 
(13, 14). However, these data are contrary to findings obtained 
after hormonal stimulation of human monocyte-derived DCs 
(15, 16). These studies reported rather an upregulation of IL-10 
in hormone-treated DCs and a TH2-promoting capacity than 
an effect on maturation markers. We have recently investigated 
the influence of two other pregnancy hormones, namely human 
chorionic gonadotropin (hCG) and luteinizing hormone (LH) 
on the number and phenotype of peripheral and local DCs in a 
murine model of disturbed fetal tolerance. The application of both 
hormones in  vivo prevented fetal rejection and was associated 
with a reduced number of total and mature DCs in the decidua. 
Moreover, there is evidence that decidual DCs isolated from 
hCG-treated animals are able to induce Treg cell generation (17). 
Consistently with our observation, other studies described an 
effect of hCG on human and murine DCs (15, 18–21). However, 
the in vivo contribution of hCG-modulated DCs remains mainly 
unclear.
In our current study, we aimed to understand the impact of 
hCG, another trophoblast-secreted factor, on DCs. By performing 
several in vitro experiments, we first analyzed the potential of two 
hCG preparations, urine-purified hCG (uhCG) and recombinant 
hCG (rhCG), to affect maturation, cytokine secretion, and T cell 
differentiation capability of BMDCs. We decided to additionally 
include rhCG in our study, as this hCG preparation displays some 
fundamental advantages compared to uhCG, and we were inter-
ested to assess potential differences between both preparations. 
Afterward, we studied the influence of hCG-modulated BMDCs 
on pregnancy outcome in an in vivo setting.
MaTerials anD MeThODs
animals
CBA/J females and DBA/2J males were purchased from 
Charles River (France) and Janvier Labs (France). All animals 
were maintained in our animal facility and treated according 
to the institutional guidelines with the ministerial approval 
(Landesverwaltungsamt Sachsen-Anhalt AZ42502-2-1125 
UNIMD). The experiments were conducted by authorized 
persons according to the Guide for Care and Use of Animals 
in Agriculture Research and Teaching. Mice were kept under 
a 12-h light/12-h dark cycle, and water and food was provided 
ad libitum. Virgin CBA/J females at the age of 8 weeks were used 
for bone marrow (BM) isolation or mated with 8- to10-week old 
DBA/2J males. DBA/2J-mated CBA/J females are known to spon-
taneously develop high abortion rates and are, therefore, used as 
abortion-prone females. After mating, females were checked for 
vaginal plug twice a day, whose appearance indicated day 0 of 
pregnancy. On day 12 of pregnancy, females were sacrificed for 
determination of the abortion rate, number of implantations, and 
for tissue processing.
generation of BMDcs
Bone marrow-derived DCs were generated using a common 
protocol described in the literature (22) with modifications. 
Briefly, femora and tibiae were removed from virgin CBA/J 
females and flushed with 2  ml Dendritic Cell Medium [DCM; 
RPMI 1640 (Invitrogen, Germany) supplemented with 10% fetal 
bovine serum (Biochrom, Germany), 1% penicillin/streptomycin 
(Invitrogen, Germany), and 50 μM 2-mercaptoethanol (Sigma, 
Germany)]. The cell suspension was centrifuged and erythrocytes 
were lysed before filtering the cells through a 100  μm sieve. 
Cells were suspended in 20  ml DCM enriched with 10  ng/ml 
granulocyte macrophage colony-stimulating factor (GM-CSF; 
PeproTech, Germany). Non-adherent cells were harvested after 
2 h of incubation and were further cultured at a concentration of 
3 × 106 cells per well in GM-CSF-enriched DCM at 37°C and 5% 
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CO2. On day 3, 40% of the medium was refreshed. Two days later 
non-adherent cells were harvested and re-suspended in fresh 
GM-CSF-enriched DCM. On day 7, BMDCs were collected for 
in vitro stimulation.
In Vitro stimulation of BMDcs
The 8 ×  105  BMDCs were cultured in 500  μl DCM per well. 
To induce maturation, BMDCs were stimulated with 2  μg/ml 
lipopoly-saccharide (LPS; Sigma, Germany) and 200  ng/ml 
interferon-γ (IFN-γ; Invitrogen, Germany). To study the effect of 
hCG on DC maturation, BMDCs were additionally treated with 
various concentrations of either uhCG (Pregnyl; EurimPharm, 
Germany; 100, 250, and 500  IU/ml) or rhCG (Ovitrelle, 
MerckSerono, UK; 50, 100, and 500 mIU/ml). BMDCs cultured in 
DCM only served as controls. After 24 h of stimulation, BMDCs 
and cell culture supernatants were collected for flow cytometry or 
cytometric bead array (CBA) analysis.
cocultures of BMDcs and T cells
The 8 × 105 BMDCs in 500 μl DCM were stimulated with LPS 
and IFN-γ in the presence or absence of 500 mIU/ml rhCG for 
24  h. Unstimulated BMDCs cultured in DCM only served as 
controls. Naïve CD4+CD25− T cells were isolated from virgin 
CBA/J females using the Regulatory T cell Isolation Kit (Miltenyi 
Biotec, Germany), following the instructions provided by the 
manufacturer. To study the potential of the treated BMDCs to 
drive T cell differentiation, 2 × 105 BMDCs and 2 × 105 T cells 
were cocultured in DCM containing 10 ng/ml IL-2, 1 μg/ml anti-
CD3, and 5 μg/ml anti-CD28 (R&D Systems, Germany) for 48 h. 
Five hours before cell harvest, 50  ng/ml phorbol 12-myristate 
13-acetate (Sigma, Germany), 500  ng/ml Ionomycin (Sigma, 
Germany), and 10 μg/ml Brefeldin A (Biolegend, UK) were added 
to the cocultures. Afterward, the number of TH1, TH2, TH17, 
and Treg cells was determined by flow cytometry.
adoptive Transfer of BMDcs
Bone marrow-derived DCs were stimulated in  vitro and then 
adoptively transferred into CBA/J females. More precisely, 
1 × 107 BMDCs were stimulated with LPS and IFN-γ in the pres-
ence or absence of 500 mIU/ml rhCG for 24 h. Afterward, 1 × 106 
BMDCs in PBS (PAA Laboratories, Germany) were injected 
intravenously. In the first set of experiments, CBA/J females 
previously mated to DBA/2J males were injected on gestational 
day 1–3. In the second set of experiments, virgin CBA/J females 
were adoptively transferred with the cells and immediately mated 
to DBA/2J males. CBA/J females that did not become pregnant 
within 3 days were excluded from the experiment.
Tissue sampling and isolation of 
Mononuclear cells
On day 12 of pregnancy, blood was obtained from CBA/J females 
by retroorbital puncture under anesthesia. Afterward, females 
were sacrificed by cervical dislocation. Spleen, thymus, and para-
aortic lymph nodes were removed, washed in ice cold PBS, and 
kept in RPMI 1640 medium at 4°C. Pregnant uteri were opened 
longitudinally and the number of implantations as well as the 
abortion rates were documented. Fetoplacental units were sepa-
rated from their implantation sites, deciduas were cut in small 
pieces and collected in HBSS without Ca2+ and Mg2+ (Sigma, 
Germany). Additionally, one piece of decidua was snap frozen 
for Real-time RT-PCR analysis. Mononuclear cells from blood, 
spleen, thymus, para-aortic lymph nodes, and decidua samples 
were isolated using our established protocol (23) and analyzed 
by flow cytometry.
Flow cytometry analysis
Bone marrow-derived DCs and T cells from in  vitro assays as 
well as mononuclear cells obtained from pregnant females were 
stained for extra- and intracellular markers as described elsewhere 
(23). The following antibodies were used: FITC-conjugated anti-
mouse CD80 (clone 16-10A1), PE-conjugated anti-mouse I-A/I-E 
(clone: M5/114.15.2), FITC-conjugated anti-mouse CD4 (clone: 
RM4-4), PE-conjugated anti-mouse Foxp3 (clone: FJK-16s), 
PE-conjugated anti-mouse TNFα (clone: MP6-XT22), PerCP-
conjugated anti-mouse IFN-γ (clone: XMG1.2), PE-conjugated 
anti-mouse IL-17 (clone: TC11-18H10), PE-conjugated anti-
mouse IL-4 (clone: 11B11), and APC-conjugated anti-mouse 
IL-10 (clone: JES5-16E3). Foxp3 antibody was purchased from 
eBioscience, Germany. All other antibodies were purchased from 
BD Biosciences, Germany.
cytokine Determination by cBarray 
analysis
To quantify cytokines in supernatants of BMDC cultures, the 
CBArray kit for IL-6, IL-10, MCP-1, TNF, and IL-12p70 (BD 
Biosciences, Germany) was used according to the instructions 
provided by the manufacturer. Briefly, cytokine capture beads 
were mixed with 50 μl of supernatants and incubated for 2 h with 
PE-conjugated detection antibodies to form sandwich complexes. 
After washing, the complexes were re-suspended and measured 
by flow cytometry.
real-Time rT-Pcr
Frozen decidual tissue was treated with Trizol® Reagent 
(Invitrogen, Germany) and disaggregated using a homogenizer 
(Ultra-Turrax T8; IKA, Germany). Isolation of RNA, cDNA 
synthesis, and real-time RT-PCR were performed as described 
elsewhere (24). For detection of IL-10 and TGF-β TaqMan 
technology was conducted using an iQ5 Multicolor RT-PCR 
Detection System (Bio-Rad Laboratories, Germany). β-Actin 
was employed as housekeeping gene and relative gene expression 
was calculated by 2−ΔCT. Primer and probe sequences are available 
upon request.
Data analysis and statistics
Analysis of data was performed using the GraphPad Prism 5.0 
software (STATCON, Germany). Data obtained from in  vitro 
assays are presented as means plus SEM. In vivo data and RT-PCR 
data are presented as medians in graphs showing individual val-
ues for each animal. In vitro data were analyzed using one-way 
ANOVA followed by Bonferroni correction for multiple com-
parisons. All other data were analyzed using the non-parametric 
FigUre 1 | Treatment with rhcg and uhcg impaired BMDc maturation. BMDCs were stimulated with LPS/IFN-γ in the presence or absence of different 
concentrations of rhCG (a) or uhCG (B) for 24 h. Unstimulated BMDCs served as controls. BMDC maturation was assessed by MHCII and CD80 expression via 
flow cytometry. Both hCG preparations hampered the maturation of activated BMDCs in a concentration-dependent manner. Each assay was repeated five times in 
duplicates. Data are presented as means plus SEM. Statistical analysis was carried out by one-way ANOVA followed by Bonferroni correction for multiple 
comparisons. *p < 0.05, **p < 0.01, ***p < 0.001.
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Mann–Whitney U test. In all cases, p < 0.05 was considered to be 
statistical significant.
resUlTs
In Vitro Maturation of BMDcs Was 
hampered by rhcg and uhcg
Previously, Wan and colleagues showed that uhCG interferes with 
BMDC maturation. Here, in addition to uhCG, we tested the effects 
of rhCG on BMDCs stimulated with LPS and IFN-γ for 24 h. Both 
hCG preparations were used to study a concentration-dependent 
effect. After 24 h of culture, we observed a significant increase 
in the number of mature CD80+MHCII+ BMDCs after LPS and 
IFN-γ stimulation (Figures 1A,B). In the presence of 50, 100, and 
500  mIU/ml rhCG, the number of mature BMDCs expressing 
CD80 and MHCII was significantly reduced when compared to 
BMDCs that were not treated with hCG (Figure 1A). In line, 250 
and 500  IU/ml uhCG significantly hampered BMDC matura-
tion (Figure 1B). A lower concentration of uhCG (100 IU/ml), 
decreased, although not significantly, CD80+MHCII+ BMDC 
numbers.
Treatment with rhcg Did not alter 
cytokine secretion of BMDcs
After we confirmed that rhCG had the same potential to interfere 
with BMDC maturation as uhCG, we focused our study on rhCG 
and evaluated whether the addition of hCG to the culture alters 
cytokine secretion by LPS/IFN-γ-stimulated BMDCs. BMDCs 
were, therefore, cultured in the presence or absence of different 
concentrations of rhCG for 24 h and analyzed for their secretion 
of IL-6, IL-10, IL-12p70, MCP-1, and TNF. None of the rhCG 
concentrations did significantly influence the secretion of any of 
the investigated cytokines (Figures 2A–E).
rhcg-Treated BMDcs Did not influence 
the Differentiation of naïve T cells in Th1, 
Th2, and Th17 cells
Next, we were interested to analyze whether BMDCs previously 
treated with rhCG were able to influence T cell differentiation 
in  vitro. BMDCs were stimulated with LPS/IFN-γ, cultured in 
the presence or absence of rhCG or left unstimulated (immature 
BMDCs). Afterward, BMDCs were cocultured with naïve T cells 
for 48 h to assess their ability to drive T cell differentiation toward 
type-1, type 2, or type-17. In the absence of BMDCs, T cell activa-
tion via the TCR resulted in a strong upregulation of the TH1 
cytokines TNF-α and IFN-γ as well as IL-17 (Figures 3A–C). IFN-γ 
and IL-17 upregulation was impaired in the presence of imma-
ture BMDCs (Figures  3B,C). Notably, mature BMDCs without 
hCG treatment further increased TNF-α upregulation in T cells 
(Figure 3A). hCG-treated BMDCs did not significantly influence 
the increase in TNF-α, IFN-γ, and IL-17 expression when com-
pared to mature BMDCs without hCG treatment (Figures 3A–C).
As for TH2 cytokines, T cell activation resulted in an upregula-
tion of IL-4, but not IL-10. The presence of both, immature and 
mature BMDCs, further increased IL-4 and IL-10 expression 
in stimulated T cells (Figures 4A,B). hCG-treated BMDCs did 
not provoke any statistically significant changes in secretion of 
IL-4 and IL-10 in T cells when compared to mature BMDCs 
(Figures 4A,B). Hence, no changes in T cell differentiation were 
observed when naïve T cells were cocultured with hCG-treated 
BMDCs.
rhcg-Treated BMDcs Provoked a Modest 
augmentation of cD4+Foxp3+ Treg cells 
within the naïve T cell Population
In addition to a potential impact on T cell differentiation, we 
evaluated whether BMDCs may influence the generation of Treg 
FigUre 2 | Treatment with rhcg did not alter cytokine secretion by activated BMDcs. BMDCs were stimulated with LPS/IFN-γ in the presence or absence 
of different concentrations of rhCG for 24 h. Unstimulated BMDCs served as controls. Secretion of IL-6 (a), IL-10 (B), IL-12p70 (c), MCP-1 (D), and TNF (e) was 
determined by CBArray analysis via flow cytometry. rhCG treatment did not influence the cytokine secretion profile of BMDCs. Each assay was repeated five times in 
duplicates. Data are presented as means plus SEM. Statistical analysis was carried out by one-way ANOVA followed by Bonferroni correction for multiple 
comparisons. **p < 0.01, ***p < 0.001.
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cells after they have been treated with rhCG. Therefore, BMDCs 
were stimulated for 24 h with LPS/IFN-γ, cultured in the absence 
or presence of rhCG or left unstimulated (immature BMDCs). 
Afterward, BMDCs were cocultured with naïve T cells. BMDCs 
did not significantly influence Foxp3 expression in naïve T cells 
(Figure 4C). However, rhCG-treated BMDCs induced a modest 
elevation of CD4+ T cells expressing Foxp3 when compared to 
mature BMDCs without hCG treatment (Figure 4C).
adoptive Transfer of rhcg-Treated BMDcs 
into abortion-Prone Females after 
conception Did not affect Fetal 
resorption
After we provided evidence that rhCG hampered BMDC 
maturation, we aimed to study the in vivo effects of hCG-treated 
BMDCs in a murine model of disturbed fetal tolerance. Based on 
the current literature, we hypothesized that adoptive transfer of 
hCG-induced tolerogenic BMDCs into abortion-prone females 
may result in an in vivo elevation of Treg cells and thereby prevent 
fetal rejection. According to our previous protocol for a transfer 
of Treg cells (23), we adoptively transferred BMDCs during early 
pregnancy stages (gd 1–3). On day 12 of pregnancy, we found an 
augmented number of CD4+ Foxp3+ Treg cells in the decidua of 
abortion-prone females that received hCG-treated BMDCs when 
compared to females that received mature BMDCs (Figure 5B). 
However, changes in the number of Treg cells were not associated 
with positive effects in pregnancy outcome as the abortion rate 
remained unchanged (Figure 5A). The number of implantations 
was also comparable between both groups (data not shown). In 
thymus (median: 0.63 vs. 0.92), spleen (median: 11.40 vs. 12.69), 
para-aortic lymph nodes (median: 8.09 vs. 8.21), and blood 
(median: 4.45 vs. 4.99) we detected comparable Treg cell numbers 
between females that received mature BMDCs or hCG-treated 
BMDC, respectively.
adoptive Transfer of hcg-Treated BMDcs 
into abortion-Prone Females Prior to 
Mating significantly increased Treg cell 
number and Diminished Fetal rejection
As the transfer of hCG-treated BMDCs after conception did not 
significantly influence Treg cell number and pregnancy outcome, 
we hypothesized that the time point for adoptive transfer was too 
late. Previous results indicated that the depletion of Treg cells prior 
to mating drastically impairs the implantation process and lead 
to an infiltration of activated T effector cells (25). Furthermore, 
adoptive transfer of Treg cells in abortion-prone animals is only 
protective when performed between gestation days 0–2 (23), 
while Treg cell depletion at later pregnancy stages only provokes 
FigUre 3 | Treatment with rhcg did not affect Th1 and Th17 differentiation capacity of BMDcs. BMDCs were stimulated with LPS/IFN-γ in the presence 
or absence of 500 mIU/ml rhCG for 24 h or left unstimulated (immature BMDCs). Afterward, BMDCs were cocultured with stimulated naïve T cells for 48 h. 
Unstimulated T cells served as controls. T cell differentiation was evaluated by the expression of the type-1 cytokines TNF-α (a) and IFN-γ (B) or the type-17 
cytokine IL-17 (c) via flow cytometry. Treatment with rhCG did not influence TH1 and TH17 differentiation. Each assay was repeated six times in duplicates. Data 
are presented as means plus SEM. Statistical analysis was carried out by one-way ANOVA followed by Bonferroni correction for multiple comparisons. *p < 0.05, 
**p < 0.01, ***p < 0.001.
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a minor increase in fetal resorption (26). These data underline 
the need for Treg cells at very early pregnancy stages to guarantee 
proper implantation and fetal development. Hence, we decided to 
transfer BMDCs prior to mating to achieve early Treg cell eleva-
tion. CD4+Foxp3+ Treg cell numbers in spleen (median: 10.88 
vs. 10.43), para-aortic lymph nodes (median: 8.96 vs. 11.15), and 
blood (median: 5.01 vs. 4.83) did not differ statistically between 
abortion-prone females that received mature BMDCs or hCG-
treated BMDCs, respectively. The application of hCG-treated 
BMDCs, however, did significantly elevate thymic and decidual 
Treg cell frequency (Figures 6B,C). Notably, application of hCG-
treated BMDCs resulted in a significant reduction in the abortion 
rate compared to mature BMDCs (Figure 6A), while both groups 
showed comparable numbers of implantations (data not shown).
Protective effect of rhcg-Treated BMDcs 
Was associated with elevated TgF-β and 
il-10 levels at the Fetal–Maternal 
interface
Finally, we analyzed whether adoptive transfer of hCG-treated 
BMDCs affected the local mRNA expression of TGF-β and IL-10, 
two anti-inflammatory molecules that have been associated with 
Treg cell function (27). In accordance to the augmented number 
of Treg cells, we found elevated TGF-β and IL-10 levels in decidual 
tissue of abortion-prone females that received hCG-treated 
BMDCs as compared to females that received mature BMDCs 
(Figures 7A,B).
DiscUssiOn
Dendritic cells are critically involved in fetal fate as they are key 
regulators of pro- and anti-fetal immune responses. These cells 
are implicated in important immune regulatory processes at dif-
ferent pregnancy stages.
Trophoblast-associated factors have been proposed to 
induce tolerogenic DCs. Within these factors, hormones, such 
as progesterone and estrogen, seem to play a major role in DC 
regulation. Interestingly, DCs derived from various origins, 
such as BM, monocytes, spleen, or decidua, are affected by 
hormonal stimulation [summarized in Ref. (28)]. Recently, we 
suggested a role for hCG in modulating DC phenotype and 
function in murine pregnancy after observing that in vivo hCG 
FigUre 5 | adoptive transfer of rhcg-treated BMDcs into abortion-prone females after conception did not affect pregnancy outcome. BMDCs were 
stimulated with LPS/IFN-γ in the presence or absence of 500 mIU/ml rhCG for 24 h. Afterward, 1 × 106 BMDCs were adoptively transferred into pregnant 
abortion-prone females at days 1–3 of gestation. On day 12 of pregnancy, females were sacrificed and the pregnancy outcome (a) as well as the number of 
decidual Treg cells (B) was determined via flow cytometry. Transfer of rhCG-treated BMDCs elevated the number of decidual Treg cells but did not influence the 
abortion rate. Data are presented as medians. Individual values are displayed for each animal. Statistical analysis was carried out by using the non-parametric 
Mann–Whitney U test.
FigUre 4 | Treatment with rhcg did not alter Th2 differentiation capacity of BMDcs had a modest effect on the potential of BMDcs to induce Treg 
cells. BMDCs were stimulated with LPS/IFN-γ in the presence or absence of 500 mIU/ml rhCG for 24 h or left unstimulated (immature BMDCs). Afterward, BMDCs 
were cocultured with stimulated naïve T cells for 48 h. Unstimulated T cells served as controls. T cell differentiation was evaluated by the expression of the type-2 
cytokines IL-4 (a) and IL-10 (B), and the number of CD4+ Foxp3+ Treg cells (c) was determined via flow cytometry. Treatment with rhCG did not alter TH2 
polarization by BMDCs but induced a modest elevation of Treg cells. Each assay was repeated six times in duplicates. Data are presented as means plus SEM. 
Statistical analysis was carried out by one-way ANOVA followed by Bonferroni correction for multiple comparisons. *p < 0.05, **p < 0.01.
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application to abortion-prone females retained uterine DCs in 
a rather immature state, further promoting Treg cell induction 
and preventing immunological rejection of the fetus (17). 
However, the precise mechanisms occurring in vivo after hCG 
application remained unclear. Thus, our present study intended 
to shed more light on the direct effects of hCG on DCs. In 
the first set of in vitro experiments, we analyzed whether two 
hCG preparations, uhCG and rhCG, are able to influence the 
FigUre 7 | adoptive transfer of hcg-treated BMDcs into abortion-prone females prior to mating augmented decidual il-10 and TgF-β expression. 
BMDCs were stimulated with LPS/IFN-γ in the presence or absence of 500 mIU/ml rhCG for 24 h. Afterward, 1 × 106 BMDCs were adoptively transferred into virgin 
animals immediately before mating. On day 12 of pregnancy, females were sacrificed and decidual expression of TGF-β and IL-10 was assessed by RT-PCR. 
Transfer of hCG-treated BMDCs increased the expression of TGF-β (a) and IL-10 (B) when compared to females treated with mature BMDCs. Data are presented 
as medians. Individual values are displayed for each animal. Statistical analysis was carried out by using the non-parametric Mann–Whitney U test. *p < 0.05.
FigUre 6 | adoptive transfer of hcg-treated BMDcs into abortion-
prone prior to mating diminished fetal resorption. BMDCs were 
stimulated with LPS/IFN-γ in the presence or absence of 500 mIU/ml rhCG 
for 24 h. Afterward, 1 × 106 BMDCs were adoptively transferred into virgin 
animals immediately before mating. On day 12 of pregnancy, females were 
sacrificed, and the pregnancy outcome (a) as well as the number of thymic 
(B) and decidual (c) Treg cells was determined via flow cytometry. Transfer of 
hCG-treated BMDCs significantly increased the number of thymic and 
decidual Treg cells. This was associated with a diminution of fetal resorption 
in the hCG-treated BMDC group. Data are presented as medians. Individual 
values are displayed for each animal. Statistical analysis was carried out by 
using the non-parametric Mann–Whitney U test. *p < 0.05, ***p < 0.001.
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maturation process, cytokine secretion, and T cell differentia-
tion capability of BMDCs. In a previous publication, Wan and 
colleagues reported that the treatment of LPS/IFN-γ-activated 
BMDCs with uhCG blocked MHCII upregulation, but did not 
alter the expression of CD80 and CD11c (20). Using an uhCG 
preparation from the same supplier we observed similar results. 
Additionally, we decided to test the efficacy of rhCG in our 
study as the usage of recombinant preparations display some 
advantages compared to urine preparations. This is primarily 
due to potential contaminations by non-hCG proteins in urine 
preparations that may influence the results. Second, uhCG 
preparations have high batch-to-batch variations that may 
decrease the reproducibility of the experiments. Moreover, in 
a recent study, we found the rhCG preparation to be slightly 
more potent in inducing Treg cells than the urine preparation 
at least in vitro (29). Here, we observed a significantly impaired 
upregulation of MHCII and CD80 expression on LPS/IFN-
γ-activated BMDCs in the presence of rhCG suggesting that 
rhCG is as effective as uhCG in blocking BMDC maturation. 
Based on these results and on the aforementioned experimental 
disadvantages of uhCG, we decided to use rhCG in all the fol-
lowing experiments. The blocking effect on BMDC maturation 
became stronger with increasing concentrations of both hCG 
preparations suggesting a concentration-dependent impact of 
hCG on BMDCs.
Secretion of different pro-inflammatory cytokines as well 
as the production of the anti-inflammatory cytokine IL-10 
was not altered in the presence of any rhCG concentration 
tested. This contradicts the study by Wan and colleagues, who 
observed a significant elevation of IL-6, IL-10, and IL-12 after 
uhCG treatment of activated BMDCs (20). In our study, we 
did not analyze cytokine secretion of BMDCs after treatment 
with uhCG. However, we may speculate that cytokine secre-
tion by activated BMDCs is differentially regulated by various 
hCG preparations. Another murine study has recently analyzed 
the effect of hCG at the fetal–maternal interface during late 
gestation. The authors could not detect alterations in IFN-γ, 
IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, and TNF-α plasma 
concentrations after in  vivo application of hCG. However, 
hCG administration provoked an increase in the proportion 
of decidual Treg cells (30). Two human studies generated DCs 
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from blood-derived monocytes and reported controversial out-
comes. While Segerer and colleagues proved an effect of hCG 
on HLA-DR upregulation which was inhibited in stimulated 
monocytes-derived DCs as well as a reduced T cell stimulatory 
capacity (18), Huck and colleagues found no significant changes 
in surface marker expression, cytokine secretion, or T cell 
stimulatory capacity in the presence of β-hCG (15). Moreover, 
Yoshimura and colleagues investigated the influence of hCG 
on myeloid and lymphoid DC subsets obtained from human 
peripheral blood. The authors observed an increment in the 
expression of maturation markers, costimulatory molecules, 
and inflammatory cytokines, as well as an elevated capacity to 
stimulate allogeneic immune responses (21). Unfortunately, 
most studies did not clearly indicate the origin of the hCG 
preparation they used impeding any conclusions about the dif-
ferent outcomes provoked by the different hCG preparations. 
Additionally, hCG-mediated effects may differ between the 
species. Thus, follow-up studies are needed to finally clarify the 
effects of rhCG and uhCG on human cells as well as underly-
ing signaling pathways. Molecules, such as IL-6, IFN-γ, and 
indoleamine 2,3-dioxygenase, were suggested to be involved in 
hCG-initiated signaling in DCs and might be involved in the 
induction of tolerogenic DCs (19, 20).
Next, we assessed whether hCG may influence T cell differ-
entiation from naïve T cells indirectly by modulating BMDCs. 
Our results revealed that treatment of BMDCs with rhCG prior 
to cocultures with stimulated naïve T cells did neither affect 
TH1, TH2, nor TH17 cell differentiation. Wan and colleagues 
reported no influence of uhCG on the TH1 and TH2 polarization 
capacity of BMDCs on naïve T cells by determining IFN-γ and 
IL-4 production. However, the authors detected a significant 
elevated IL-10 production in cocultures between naïve T cells 
and hCG-treated BMDCs, when compared to cocultures without 
hCG treatment (20). This could not be observed in our experi-
ments suggesting that uhCG and rhCG not only differ in respect 
to their influence on the cytokine profile of BMDCs but also on 
the T cell polarization capacity. These observations might be of 
interest for the usage of hCG preparations in patients undergoing 
assisted reproductive techniques. uhCG and rhCG preparations 
are usually applied for ovulation induction and luteal support. 
Depending on the applied hCG preparation, the immune 
system of the patient may react differentially. Several studies 
compared the efficacy of uhCG and rhCG in assisted reproduc-
tive techniques. Recently, Youssef and colleagues performed a 
meta-analysis to assess the potency of both hCG preparations in 
subfertile women undergoing in vitro fertilization and intra cyto-
plasmic sperm injection cycles. The authors found no evidence 
for a difference between rhCG and uhCG concerning live birth 
or ongoing pregnancy rates (31).
It has been proposed that hCG treatment might be helpful in 
the prevention of threatened abortions (32). Here, we addressed 
the question whether the adoptive transfer of hCG-modulated 
BMDCs may prevent fetal rejection in a murine abortion-
prone model. In a first set of experiments, hCG-treated or 
mature BMDCs were adoptively transferred at very early 
pregnancy stages according to our previously used protocol 
for adoptive transfer of Treg cells (23). Adoptive transfer of 
hCG-treated BMDCs elevated Treg cell numbers directly at 
the fetal–maternal interface. However, this did not result in 
changes of the abortion rate or number of implantations. Thus, 
we assumed that adoptive transfer of BMDCs was too late to 
influence pregnancy outcome. Next, we adoptively transferred 
BMDCs to abortion-prone females prior to mating. Only 
those females that had a plug within the next 3 days following 
BMDC treatment were included in the study. Transfer of hCG-
treated BMDCs could diminish the abortion rate compared 
to females that had been transferred with mature BMDCs. 
This effect was accompanied by a significant augmentation of 
the peripheral and uterine Treg number in the hCG-treated 
BMDC group that may account for the observed effect on fetal 
survival. Using a similar mouse model, Blois and colleagues 
adoptively transferred syngeneic BMDCs into abortion-prone 
females and showed a significant reduction in fetal resorption, 
which was associated with decreased serum IL-6 levels (33). 
Unfortunately, the authors did not test whether the Treg cell 
number was changed after BMDC transfer. However, in a 
follow-up study, Miranda and colleagues showed that synge-
neic DC therapy increased the number of CD8 and γδ cells 
and induced TGF-β1 and PIBF expression (34). In line, transfer 
of hCG-treated BMDCs provoked an elevation of IL-10 and 
TGF-β in decidual tissue. Therefore, it is tempting to speculate 
that transfer of tolerogenic BMDCs induced a local elevation of 
T cell populations with regulatory properties producing preg-
nancy-protective cytokines like IL-10 and TGF-β (35). An early 
Treg cell augmentation is a prerequisite for proper blastocyst 
implantation, as depletion of Treg cells prior to mating has been 
associated with implantation failure (25). Treg cell deficiency 
resulted in uterine inflammation and fibrosis suggesting that 
at this early pregnancy time point Treg cells may counteract 
pro-inflammatory events occurring during implantation and 
thereby create a uterine environment that supports nidation of 
the embryo. As anti-inflammatory cytokines, we propose IL-10 
and TGF-β to be involved in this process.
Interestingly, Blois and colleagues found that fetal protection 
was short lived as females that became pregnant more than 2 days 
after transfer had abortions while females that became pregnant 
during the first 2  days had no abortions. In our present study, 
we could not observe a time-dependent effect between BMDC 
transfer and pregnancy establishment. However, we found that 
BMDCs that were transferred after mating did not affect fetal 
resorption suggesting that additionally to a short-lived effect, 
protective mechanisms induced by DCs have to take place very 
early in pregnancy.
In conclusion, our results propose a direct effect of rhCG 
on DCs by retaining these cells in a rather immature, thus 
tolerogenic state in vitro. Moreover, we showed for the first time 
that in vitro rhCG-modulated DCs are fully functional in vivo. 
When adoptively transferred prior to mating, hCG-modulated 
DCs increased Treg cell numbers and protected fetuses from 
rejection. Thus, our data contribute to a better understanding 
on the in  vitro and in  vivo effects of hCG on DCs. In normal 
fertile women, hCG levels rapidly increase after blastocyst 
implantation. Before pregnancy, in the pre-ovulatory phase of 
the menstrual cycle, small quantities of pituitary hCG can be 
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detected. Pituitary hCG has been reported to possess physical, 
immunological, and biological similarities to placental hCG 
(36). However, until today, there is no evidence that pituitary 
hCG can modulate DCs even before pregnancy arises and sup-
port successful pregnancy establishment. Thus, further studies 
are required to validate our observations made in the murine 
system for normal fertile women as humans and mice display 
some species specific differences in reproductive processes (37). 
However, our findings support the usage of hCG in the treatment 
of subfertile patients where hCG is applied before fertilization to 
induce final oocyte maturation. Additionally, hCG preparations 
obtained from different sources seem to affect DCs differentially. 
Therefore, the clinical application of hCG should be taken with 
caution.
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